Prognostic biomarkers may be used in clinical knee osteoarthritis to identify subgroups in whom the disease progresses at different rates. This could facilitate our understanding of the pathogenesis and allow us to differentiate phenotypes within a heterogeneous knee osteoarthritis population. Ultimately, such findings may help facilitate the development of disease-modifying osteoarthritis drugs (DMOADs).
No takes yet. Share an insight, caveat, or question.
Attur et al. (2012) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: